Menarini and Insilico Medicine Enter Global License Agreement for Novel KAT6 Inhibitor (IMAGE)

InSilico Medicine

Menarini and Insilico Medicine Enter Global License Agreement for Novel KAT6 Inhibitor

Caption

The agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.

 

Credit

Insilico Medicine

Usage Restrictions

none

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.